The Recovery® G2® Filter System – Femoral and Jugular/Subclavian Delivery Kits are indicated for use in the prevention of recurrent pulmonary embolism via permanent placement in the vena cava in the following situations:

Pulmonary thromboembolism when anticoagulants are contraindicated. .
Failure of anticoagulant therapy for thromboembolic disease. .
Emergency treatment following massive pulmonary embolism where anticipated . benefits of conventional therapy are reduced.
Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed . or is contraindicated.
Recovery® G2® Filter may be removed according to the instructions supplied . under the section labeled: Optional Procedure for Filter Removal.

Device Description

The Recovery® G2 Filter consists of 12, shape-memory nitinol wires emanating from a central nitinol sleeve. These 12 wires form two levels of emboli filtration: the legs provide the lower level of filtration and the arms provide the upper level of filtration. The Recovery® G2® Filter is intended to be used in the inferior vena cava with diameters less than or equal to 28 mm. The predicate device filter is identical to the subject device filter.

The Recovery® G2® Filter System - Femoral Delivery Kit consists of a 7 French I.D. introducer catheter and dilator set (Kit A) and a storage tube preloaded with the Recovery® G2® Filter and pusher system (Kit B). Kit A (introducer catheter and dilator) is used to gain access to the inferior vena cava via a femoral approach. The dilator accepts a 0.038" guidewire and the introducer catheter has 2 radiopaque marker bands on the distal end to assist in filter delivery. The pusher system (Kit B), designed to pass through the introducer catheter, consists of a grooved segment designed to hold and properly orient the filter legs and a flexible nitinol wire with a pad at the end that pushes on the filter apex.

The Recovery® G2® Filter System – Jugular/Subclavian Delivery Kit consists of a 10 French I.D. introducer sheath and dilator set and a delivery device preloaded with the Recovery® G2® Filter. The introducer sheath and dilator are used to gain access to the inferior vena cava via a jugular or subclavian approach. The dilator accepts a 0.038" guidewire and enables a contrast medium power injection up to 800 psi maximum pressure. The introducer sheath contains a radiopaque tip and hemostasis valve with a side port for injecting contrast medium via a syringe. The delivery device fits within the introducer sheath and consists of a side port for saline infusion and a delivery mechanism to deploy the Recovery® G2® Filter. The delivery device contains a spline cap that mechanically separates the filter hooks from one another in a unique pattern to properly orient the filter legs and contains a pusher wire consisting of a flexible nitinol wire with a pad at the end that pushes on the filter sleeve.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and the study that proves the device meets those criteria:

Acceptance Criteria and Device Performance for Recovery® G2® Filter System

1. Table of Acceptance Criteria and Reported Device Performance:

Acceptance Criteria (Implied)	Reported Device Performance
Safe and effective removal (retrieval) of the filter.	Retrieval of the Recovery® G2® Filter was achieved in 95.1% of the study subjects undergoing a retrieval procedure.
Acceptable indwell time for successful retrieval.	The mean filter indwell time in the retrieved subjects was 140.0 ± 62.1 days (median 143.5, range 5 - 300).
Substantial equivalence to predicate devices for intended use, application, user population, basic design, fundamental scientific technology, performance, and sterilization method.	The change to the predicate devices only affected the indications for use. The subject device is stated to be "substantially equivalent" to predicate devices.

Important Note: The document focuses heavily on the retrieval aspect as a key new feature and therefore the primary performance metric. The acceptance criteria for other aspects of the device's function (e.g., preventing pulmonary embolism) are implicitly covered by demonstrating substantial equivalence to the predicate devices, which were presumably approved based on their own performance data.

2. Sample Size and Data Provenance for the Test Set:

Sample Size: The document does not explicitly state the total number of subjects in the prospective clinical study. It only mentions "95.1% of the study subjects undergoing a retrieval procedure," implying that the sample size is the number of subjects who underwent an attempt at retrieval. To calculate this, if X is the total number of subjects in the study and Y is the number of subjects undergoing retrieval, then 95.1% of Y were successfully retrieved. Without Y, the exact sample size for the retrieval test is unknown, but it is the number of retrieved subjects.
Data Provenance: The study was a "prospective, multi-center, nonrandomized clinical study." The country of origin is not specified, but the submission is to the U.S. FDA, suggesting it was likely conducted in the U.S. or under U.S. regulatory guidelines.

3. Number of Experts and Qualifications for Ground Truth:

The document does not provide information on the number of experts used or their qualifications for establishing ground truth for the test set. Given the nature of a clinical study for a medical device like this, ground truth would likely be established through clinical outcomes and assessments performed by medical professionals (e.g., interventional radiologists, cardiologists), but specific details are not provided in this summary.

4. Adjudication Method for the Test Set:

The document does not specify any adjudication method (e.g., 2+1, 3+1, none) for the test set.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

An MRMC comparative effectiveness study was not conducted or reported in this summary. The study described is a clinical study evaluating the device's retrieval success rate. There is no mention of comparing human readers with and without AI assistance, as this is solely a medical device (filter) submission, not an AI software submission.

6. Standalone Performance Study:

The primary performance study reported is a standalone clinical study evaluating the retrieval safety and success rate of the Recovery® G2® Filter in human subjects. This is an "algorithm only (device only)" performance in the context of device function, not an AI algorithm. Bench and animal testing were also performed, indicating standalone performance in controlled environments.

7. Type of Ground Truth Used:

The ground truth used for the reported retrieval success rate was clinical outcome data. Specifically, it was the observable success or failure of the filter retrieval procedure in human patients.

8. Sample Size for the Training Set:

The document does not report a "training set" as this is a medical device (filter) submission, not a machine learning or AI software submission. The "training set" concept is typically relevant to AI models.

9. How Ground Truth for the Training Set Was Established:

As there is no training set in the context of this device submission, this question is not applicable.

Summary

{0}------------------------------------------------

K073090 page 1 of 4

Recovery® G2® Filter System – Femoral and Jugular/Subclavian Delivery Kit 510(k) Summary 21 CFR 807.92

As required by the Safe Medical Devices Act of 1990, coded under Section 513, Part (I)(3)(A) of the Food, Drug and Cosmetic Act, a summary of the information upon which substantial equivalence determination is based as follows:

1. Submitter Information:

Applicant:	Bard Peripheral Vascular, Inc1625 West 3rd StreetTempe, Arizona 85281	JAN 1 5 2008
Phone:	480-303-2524
Fax:	480-449-2546
Contact:	Genevieve BalutowskiAssociate Project Manager, Regulatory Affairs

2. Subject Device:

Device Trade Name:	Recovery® G2® Filter System – Femoral Delivery Kitand Recovery® G2 Filter System – Jugular/SubclavianDelivery Kit
Common or Usual Name:	Filter, Intravascular, Cardiovascular
Classification:	Class II

Classification Panel: Cardiovascular

3. Predicate Devices:

G2™ Filter System Femoral Delivery Kit (K062887)
G2™ Filter System Jugular/Subclavian Delivery Kit (K052578)

{1}------------------------------------------------

4. Summary of Change:

The change to the predicate devices, G2™ Filter System - Femoral Delivery Kit and the G2™ Filter System - Jugular/Subclavian Delivery Kit, only affect the indications for use. Indications for use of the subject device, Recovery® G2® Filter System – Femoral and Jugular Delivery Kits, are identical to the indications for use of the predicate devices, with the exception of the last bullet point that notes:

"Recovery® G2® Filter may be removed according to the instructions supplied under the section labeled: Optional Procedure for Filter Removal."

5. Device Description:

Recovery® G2® Filter System - Femoral and Jugular/Subclavian Delivery Kits

{2}------------------------------------------------

K073090 Page 3 of 4

side port for injecting contrast medium via a syringe. The delivery device fits within the introducer sheath and consists of a side port for saline infusion and a delivery mechanism to deploy the Recovery® G2® Filter. The delivery device contains a spline cap that mechanically separates the filter hooks from one another in a unique pattern to properly orient the filter legs and contains a pusher wire consisting of a flexible nitinol wire with a pad at the end that pushes on the filter sleeve.

6. Intended Use of Device:

The subject device, the Recovery® G2® Filter System - Femoral and Jugular/Subclavian Delivery Kits, is indicated for use in the prevention of recurrent pulmonary embolism via permanent placement in the vena cava in the following situations:

Pulmonary thromboembolism when anticoagulants are contraindicated. .
Failure of anticoagulant therapy for thromboembolic disease. .
Emergency treatment following massive pulmonary embolism where anticipated . benefits of conventional therapy are reduced.
Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed . or is contraindicated.
Recovery® G2® Filter may be removed according to the instructions supplied . under the section labeled: Optional Procedure for Filter Removal.

7. Performance Data:

The Recovery® G2® Filter System - Femoral and Jugular/Subclavian Delivery Kits were evaluated via data collected from bench and animal testing. Additionally, the safety of retrieval of the Recovery® G2® Filter was evaluated in a prospective, multi-center, nonrandomized clinical study. Retrieval of the Recovery® G2® Filter was achieved in 95.1% of the study subjects undergoing a retrieval procedure. The mean filter indwell time in the retrieved subjects was 140.0 ± 62.1 days (median 143.5, range 5 - 300).

8. Technological Comparison to Predicate Device:

The technological characteristics of the subject device, the Recovery® G2® Filter System - Femoral and Jugular/Subclavian Delivery Kits, are substantially equivalent to

{3}------------------------------------------------

KO73090 Auge 464

those of the predicate devices, the G2® Filter System - Femoral Delivery Kit and the G2® Filter System - Jugular/Subclavian Delivery Kit, in terms of intended use, application, user population, basic design, fundamental scientific technology, performance, and sterilization method.

{4}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

DEPARTMENT OF HEALTH & HUMAN SERVICES · USA

JAN 1 5 2008

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Public Health Service

Bard Peripheral Vascular, Inc. c/o Ms. Genevieve Balutowski Senior Regulatory Affairs Specialist P.O. Box 1740 Tempe, AZ 85280

Re: K073090

Trade Name: Recovery G2 Filter System - Femoral and Jugular/Subclavian Delivery Kits Regulation Number: 21 CFR 870.3375 Regulation Name: Cardiovascular Intravascular Filter Regulatory Class: Class II (two) Product Code: DTK Dated: October 31, 2007 Received: November 1, 2007

Dear Ms. Balutowski:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{5}------------------------------------------------

Page 2 - Ms. Genevieve Balutowski

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Bram D. Zuckerman, M.D.

Brand D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

Indications for Use

510(k) Number (if known): KO7 30 90

Device Name: Recovery® G2® Filter System – Femoral and Jugular/Subclavian Delivery Kits

Indications for Use:

Pulmonary thromboembolism when anticoagulants are contraindicated. .
Failure of anticoagulant therapy for thromboembolic disease. .
Emergency treatment following massive pulmonary embolism where anticipated . benefits of conventional therapy are reduced.
. Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated.
Recovery® G2® Filter may be removed according to the instructions supplied . under the section labeled: Optional Procedure for Filter Removal.

× Prescription Use (Part21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K073090

Page 1 of 1

TRADE SECRET/CONFIDENTIAL INFORMATION Notify CR Bard Before Releasing this Document.

Image /page/6/Picture/18 description: The image shows the word "BARD" in a bold, sans-serif font. The letters are outlined in black, and the interior of the letters is white. The letters are evenly spaced and appear to be of uniform size.

Regulation Number and Section

§ 870.3375 Cardiovascular intravascular filter.

(a)
Identification. A cardiovascular intravascular filter is an implant that is placed in the inferior vena cava for the purpose of preventing pulmonary thromboemboli (blood clots generated in the lower limbs and broken loose into the blood stream) from flowing into the right side of the heart and the pulmonary circulation.(b)
Classification. Class II. The special controls for this device are:(1) “Use of International Standards Organization's ISO 10993 ‘Biological Evaluation of Medical Devices Part I: Evaluation and Testing,’ ” and
(2) FDA's:
(i) “510(k) Sterility Review Guidance and Revision of 2/12/90 (K90-1)” and
(ii) “Guidance for Cardiovascular Intravascular Filter 510(k) Submissions.”